• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cardiovasc Diagn Ther . Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,679 patients from 53 studies

tetano

Editor, Senior Moderator
Cardiovasc Diagn Ther


. 2020 Aug;10(4):667-677.
doi: 10.21037/cdt-20-535.
Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,679 patients from 53 studies


Zhi-Chun Gu[SUP] 1 [/SUP], Chi Zhang[SUP] 1 [/SUP], Ling-Cong Kong[SUP] 1 2 [/SUP], Long Shen[SUP] 1 2 [/SUP], Zheng Li[SUP] 1 2 [/SUP], Heng Ge[SUP] 1 2 [/SUP], Hou-Wen Lin[SUP] 1 [/SUP], Jun Pu[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) has become global pandemic and resulted in considerable morbidity and mortality since December 2019. Information on the incidence of myocardial injury remains scarce.
Methods: English-language databases (PubMed, Embase, Cochrane), Chinese-language databases (CNKI, VIP, WANFANG), and preprint platform were searched to identify studies that reported the myocardial injury data in COVID-19 patients. Random-effects meta-analyses were used to derive the pooled incidence and relative risks (RRs) of myocardial injury. Variations by disease severity were examined by subgroup analyses. Sensitivity analyses were performed to strengthen the results. Meta-regression was applied to explore the risk factors associated with myocardial injury.
Results: A total of 53 studies involving 7,679 patients were included. The pooled incidence of myocardial injury was 21% [95% confidence interval (CI), 17-25%; I[SUP]2[/SUP], 96.5%]. The highest incidence of myocardial injury was found in non-survivors (66%; 95 CI%, 54-78%; I[SUP]2[/SUP], 85.7%), followed by severe patients (43%; 95 CI%, 33-53%; I[SUP]2[/SUP], 93.0%) and non-severe patients (11%; 95 CI%, 7-15%; I[SUP]2[/SUP], 95.2%). Higher risk of myocardial injury was detected in severe patients than non-severe patients (RR, 5.74; 95% CI, 3.74-8.79; I[SUP]2[/SUP], 86.8%). All the sensitivity analyses confirmed the robustness of primacy results.
Conclusions: This meta-analysis showed that myocardial injury occurred in 21% of COVID-19 patients. An elevated rate was observed in non-survivors (66%) and severe patients (43%). Severe patients had a 4.74-fold increase in the risk of myocardial injury than non-severe patients. Aggressive strategy may be considered for COVID-19 patients at high risk of myocardial injury.

Keywords: Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2); coronavirus disease 2019 (COVID-19); incidence; meta-analysis; myocardial injury.
 
Back
Top Bottom